我要投票 乐普LEPU在医疗器械行业中的票数:589
· 外 推 电 报 ·
2025-11-23 13:54:15 星期日

【乐普LEPU是哪个国家的品牌?】

乐普LEPU是什么牌子?「乐普LEPU」是乐普(北京)医疗器械股份有限公司旗下著名品牌。该品牌发源于北京市,由创始人蒲忠杰在1999-06-11期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力乐普LEPU品牌出海!将品牌入驻外推网,定制乐普LEPU品牌推广信息,可以显著提高乐普LEPU产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

创立于1999年,集产品研发、生产、销售于一体,专业从事植介入诊疗器械及设备领域的医疗产品产业集团,其心血管病植介入诊疗器械在业内颇具影响力

乐普(北京)医疗器械股份有限公司(简称乐普医疗集团)创立于1999年,股份制集团上市公司(股票代码300003),公司销售网络遍布全中国及95个国家和地区,年营业收入46亿元人民币。 通过坚持技术创新、合作共赢的发展之路,乐普医疗集团正努力建立四位一体的心血管全产业链平台型企业。

乐普(北京)医疗器械股份有限公司创立于1999年,总部位于北京市中关村科技园区昌平园。公司是从事冠状动脉药物支架、先心封堵器、心脏瓣膜、造影机等心血管疾病植介入诊疗器械及设备产品研发、生产与销售的中外合资央企控股企业,是2009年在深交所创业板上市的28家企业之一。公司目前拥有国内外8家子公司,产品临床应用覆盖全国1200家以上心脏诊疗中心,已发展成为国内从事的心血管病植介入诊疗器械与设备的医疗产品产业集团。

乐普公司集合了材料、机械、电子、精密加工、临床医学等各类专业人才,拥有一支在产品研发、质量控制、临床验证、市场开拓、企业管理等方面专业的经验丰富的人才队伍。研制开发涵盖:冠心病、结构性心脏病、心脏节律、预先和术后诊断及诊疗设备五大领域的植介入产品,取得了一系列具有国内、国际水平的研究成果。是国内规模较大的也是拥有多种技术特点药物支架产品的制造企业,是亚洲较大的人工心脏瓣膜制造企业,是国内心脏起搏器的先行者,是国内心脏封堵器、血管造影机的市场佼佼者,是国内研制肾动脉射频消融导管的企业。

乐普公司疗创立以来,先后承担了国家发改委高技术产业化示范工程项目、国家科技部863计划发展项目、科技支撑计划项目等几十项国家重大课题。2013年,以乐普公司为依托单位,组建了“国家心脏病植介入诊疗器械及设备工程技术研究中心”,将进一步推动建设国家心脏病植介入诊疗器械及设备技术创新、产业化和人才聚集的平台,攻克一系列行业发展的核心技术和核心工艺,推动我国心脏病植介入医疗事业的迅速发展。我们秉承“以科技的力量,从心点燃生命的光辉”,为广大医护工作者提供更好更强的医疗产品与技术,使更多心血管病患者能够用得上用得起中国自己的医疗技术和产品。


英文翻译:Founded in 1999, it is a medical product industry group integrating product R & D, production and sales, specializing in the field of interventional devices and equipment. Its cardiovascular interventional devices have great influence in the industry. Lepu (Beijing) Medical Devices Co., Ltd. (referred to as Lepu medical group) was founded in 1999. The joint stock group listed company (Stock Code: 300003) )The company's sales network covers all over China and 95 countries and regions, with an annual operating revenue of 4.6 billion yuan. By adhering to the development path of technological innovation and win-win cooperation, Lepu medical group is striving to establish a platform enterprise of four in one cardiovascular industry chain. Lepu (Beijing) medical equipment Co., Ltd. was founded in 1999 and its headquarter is located in Changping Park, Zhongguancun Science and Technology Park, Beijing. The company is a Sino foreign joint-venture state-owned enterprise holding the R & D, production and sales of cardiovascular disease interventional devices and equipment products, such as coronary drug stent, precordial occluder, heart valve and contrast machine. It is one of the 28 enterprises listed on the growth enterprise market of Shenzhen Stock Exchange in 2009. At present, the company has 8 subsidiaries at home and abroad, with clinical application covering more than 1200 cardiac diagnosis and treatment centers across the country, and has developed into a domestic medical product industry group engaged in cardiovascular interventional diagnosis and treatment equipment and equipment. Lepu company has gathered all kinds of professional talents in materials, machinery, electronics, precision processing, clinical medicine, etc., and has a professional team with rich experience in product research and development, quality control, clinical verification, market development, enterprise management, etc. The research and development covers five fields: coronary heart disease, structural heart disease, heart rhythm, pre and post-operative diagnosis and treatment equipment, and a series of research results with domestic and international level have been achieved. It is a large-scale manufacturing enterprise with a variety of technical characteristics of drug stent products in China, a large artificial heart valve manufacturing enterprise in Asia, a pioneer in domestic cardiac pacemaker, a market leader in domestic cardiac occluder and angiograph, and a domestic enterprise in the research and development of renal artery radiofrequency catheter ablation. Since its establishment, Lepu company has successively undertaken dozens of national major projects, such as the high-tech industrialization demonstration project of the national development and Reform Commission, the 863 program development project of the Ministry of science and technology, and the science and technology support program project. In 2013, with Lepu company as the supporting unit, the "National Center for engineering and technology research of heart disease plant intervention diagnosis and treatment equipment and equipment" was established, which will further promote the construction of a national platform for innovation, industrialization and talent accumulation of heart disease plant intervention diagnosis and treatment equipment and equipment, attack a series of core technologies and core processes for industry development, and promote China's heart disease plant intervention medical affairs The rapid development of the industry. We adhere to the principle of "lighting up the brilliance of life from the heart with the power of science and technology" to provide better and stronger medical products and technologies for medical workers, so that more patients with cardiovascular diseases can use their own medical technologies and products in China.

本文链接: https://www.waitui.com/brand/56660df8a.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

天赐材料北美首座电解液工厂破土动工,总投资约2亿美元

36氪获悉,据天赐材料消息,11月21日,天赐材料位于美国德州贝敦的北美首座电解液工厂正式破土动工。该项目总投资约2亿美元,建成后将形成年产20万吨电解液产能。

2小时前

月球制造+质量投射器,马斯克瞄准每年100太瓦太空能源产能

埃隆·马斯克在20日发文称“星舰(Starship)应能每年向轨道运送约300吉瓦的太阳能人工智能卫星,甚至可能达到500吉瓦。”一博主对此表示,“若以每年300吉瓦(GW/yr)的速度增长,仅需12年就能超过全球当前的总发电量(约3.5太瓦)。”23日,马斯克回应称,“月球制造结合质量投射器,将能实现每年超过100太瓦的(产能/能量输出)。”(新浪财经)

2小时前

网传小米汽车工厂内电池产线起火,小米官方澄清

36氪获悉,小米公司发言人发文表示,近日网络谣传的所谓“小米汽车工厂内电池产线起火”相关谣言,严正辟谣澄清如下:2024年,小米汽车工厂电池车间的生产设备,在调试优化过程中,操作人员在手动模式下调试操作失误,使得AGV(自动导引车)上托运的电池包与设备发生磕碰,电芯被划伤,从而造成该电池包短路引起明火,火情极小。车间迅速启动处理预案,相关火情被迅速扑灭,未波及其他生产区域,且没有造成人员受伤。向大家特别说明:此次事件确实是生产流程调试工作中的偏差,但并不是电池本身存在设计缺陷、材料问题或制造瑕疵。小米汽车所有车型电池包均坚持超高标准开发,小米SU7、小米YU7电池均满足电池国标相关要求,请广大车主放心。此外,同期网络还流传一则所谓“电池车间事件墙展示”视频,我们一并查证确认:相关图片系2024年初,电池车间相关设备在“最初调试”期间的检测验证问题管理看板,且相关问题在量产阶段之前均已解决。

2小时前

波士顿联储行长Collins:尚未决定是否支持12月降息

波士顿联储行长Susan Collins在暗示可能倾向于维持利率不变的一天后表示,她尚未决定在美联储下次政策会议上如何投票。“我还没有做出决定,我不会在真正参加会议之前做出决定,”Collins周六在波士顿联储年度经济会议间隙对记者表示。“还有数据将公布。”(新浪财经)

2小时前

确立规范人员资质等,六项航空应急救援领域团体标准发布

昨天,《直升机索降作业操作指导》《直升机医疗转运及机上操作指导》《直升机舱内物资投送操作指南》等六项航空应急救援领域团体标准在江西景德镇发布,标准系统性填补了相关领域的空白,形成了覆盖“人、机、料、法、环”全要素的操作规范体系。(央视新闻)

2小时前

本页详细列出关于乐普LEPU的品牌信息,含品牌所属公司介绍,乐普LEPU所处行业的品牌地位及优势。
咨询